FDA Clears AI-Enabled Chest CT Software for Aortic Analysis
The newly cleared Aview Aorta Metrics software reportedly offers automated segmentation of aortic regions. It also classifies aortic zones based on chest CT images.
Read the original →Every story in this issue with a short summary, so you can decide what to read before leaving the site. Summaries are written by AI (Claude) only from each publisher's own description and checked by Jev for anything not in that description. They are not full translations. Follow "Read the original" for the full story.
The newly cleared Aview Aorta Metrics software reportedly offers automated segmentation of aortic regions. It also classifies aortic zones based on chest CT images.
Read the original →A symposium addresses AI in diagnosis, treatment, surgery and patient care. It uses 70 years of clinical data.
Read the original →A new federated learning framework for chest X-ray analysis reports modest accuracy gains over existing methods. It aligns explanations across simulated hospital clients under a certified approach.
Read the original →A two-cohort study evaluates machine learning for predicting medium-term Type 2 diabetes risk in patients with biopsy-confirmed NAFLD.
Read the original →A pilot randomized trial at Kyoto University Hospital tested a workflow in which clinicians review drafts generated by large language models. It found that the workflow improved most expert-rated quality domains for discharge summaries.
Read the original →The payoff from healthcare artificial intelligence can take time. Three experts share how leaders can demonstrate value from AI and use it to support the health system's strategic priorities.
Read the original →This column follows an earlier piece that examined medical AI from a business perspective, focusing on opportunities for technology companies. It turns to a more fundamental question beyond innovation and new markets.
Read the original →The article presents an operational roadmap for scaling agentic AI and physical hospital robotics beyond pilots. It covers ROI, governance and adoption strategy.
Read the original →Artificial intelligence is influencing the choices behind drug development, from molecular design to trial recruitment.
Read the original →The risks and behavior of autonomous, agentic AI in health care remain relatively uncharted, so regulators such as the FDA are taking a cautious approach to clearance. The FDA is soliciting industry feedback on evaluation frameworks. The article says rigorous, standardized oversight is essential for patient safety and clinical reliability before these tools enter real-world practice.
Read the original →The article describes a hospital trust eighteen months into using an AI tool that flags suspected abnormalities on chest X-rays, with no formal check on whether it still performs as it did on day one. It says UK regulation of AI medical devices is now turning toward that question.
Read the original →As medical AI advances, lawmakers and health leaders face the question of who is liable when the technology fails.
Read the original →A new narrative review finds that medical vision-language AI models show strong benchmark results. It also reports inconsistent evaluation reporting, hallucination risks and narrow training data.
Read the original →Years earlier, a powerful AI system was developed that could detect pancreatic cancer, described as the "silent killer," with the naked eye. Academia is paying keen attention.
Read the original →The technology is described as helping medical professionals identify patients who need prioritized urgent care. It is also presented as giving employers a data-driven way to screen for high-risk individuals with potential health conditions. The description says it uses health assessment algorithms to support care triage and workplace wellness initiatives.
Read the original →Global big tech companies are releasing a series of research findings evaluating the clinical performance of medical AI.
Read the original →New techniques will be the focus of the Italian Society's forthcoming Congress. The description says a number of unknowns remain between the promises and their large-scale implementation.
Read the original →This column follows an earlier one that covered medical AI from a business perspective and the opportunities for technology companies. It asks what these technologies change for the doctors who use them and the patients who rely on those doctors. The author says the value of medical innovation lies in improving the quality and accessibility of care, and that remarkable changes in how care is delivered are already under way.
Read the original →Researchers at Fukushima Medical University, Chiba University and the National Institute of Health and Crisis Management (JIHS), working with Fcom Corporation, developed a web platform called "Fukushima Medical University Diabetes Future Prediction Navi". It uses AI to classify diabetes into five subtypes and estimate future risks of complications and comorbidities, including diabetic kidney disease, dialysis initiation and cardiovascular disorders.
Read the original →Samsung Seoul Hospital is working to put humanoid robots for surgery into practical use. Generative AI predicts the situation and the robot acts accordingly. When a surgeon gives a spoken command, the robot moves its hands within two seconds, handing over instruments and returning them to their original position after use.
Read the original →Tairex, which originated at Tsinghua University, announced MHAC, in which 54 AI doctors join clinical care alongside physicians. The figures of over 96% on MedQA and roughly 30% efficiency improvement are self-reported by the company.
Read the original →